Major Finding: A shared neoantigen vaccine plus immune checkpoint blockade was well-tolerated in advanced solid tumors. Concept: Preliminary clinical activity was observed along with a hierarchy of ...
Genentech’s alectinib (Alecensa) received FDA approval for adjuvant treatment of non–small cell lung cancer (NSCLC) in patients with ALK-positive disease. The decision was based on the phase III ALINA ...
1Department of Pathology, Stanford University School of Medicine, Palo Alto, California.
1Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 2Cancer Center, Massachusetts General Hospital, Harvard Medical School, ...
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
The primary treatment for glioblastoma (GBM) is removing the tumor mass as defined by magnetic resonance imaging (MRI). However, MRI has limited diagnostic and predictive value. Tumor-associated ...
The primary treatment for glioblastoma (GBM) is removing the tumor mass as defined by magnetic resonance imaging (MRI). However, MRI has limited diagnostic and predictive value. Tumor-associated ...
1Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, China. 2Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
MyProstateScore 2.0 (MPS2) proved more accurate at detecting prostate cancer than PSA and other biomarkers, researchers reported, sparing men more invasive testing, such as prostate biopsies and MRI ...
1Cancer Moonshot, White House, Office of Science and Technology Policy, Washington, District of Columbia. Search for other works by this author on: 1Cancer Moonshot, White House, Office of Science and ...
2Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands. *Corresponding Author: Ferenc A. Scheeren, Department of Dermatology, Leiden University Medical Center, ...